Kalamazoo, Mich. (PRWEB) April 10, 2015
Armune BioScience announced today the official opening of laboratory services in its CLIA registered laboratory in Ann Arbor, MI. The company has initiated the national availability of Apifiny™ - the only tumor specific, non-PSA blood test designed to aid clinicians in the detection of prostate cancer.
“The proprietary technology of Armune BioScience has significant potential to meet an area of large unmet needs in prostate cancer diagnostic testing,” said David A. Esposito, President and CEO of Armune. “Our team is prepared to execute on the large opportunity for Apifiny to aid clinicians in the detection of prostate cancer.”
Armune develops and commercializes autoantibody technology licensed from the University of Michigan that was developed under the direction of Arul Chinnaiyan, MD, PhD. Dr. Chinnaiyan commented, “There are a number of challenges clinicians face with effectively diagnosing prostate cancer. Our research team is honored to see our original work being available to community based urologists to potentially impact care in a meaningful way.”
“We are excited to see the collaboration of research at the University of Michigan transferred into the commercial operations of a Michigan-based life science company,” said Robin Rasor, Managing Director of Licensing in the Office of Technology Transfer at Michigan. “The research at Michigan continues to drive innovation and positively impact human health.”
Armune officially opens the laboratory for business today and is prepared to process testing requests from clinicians and reference laboratories. Clinicians and patients interested in gaining access to Apifiny should call 844-427-6863 or request information from the company’s website at http://www.armune.com.
Armune continues to raise funds through its current Series A round of investment to support the growth of the business. Interested investors should contact Eli Thomssen, Chief Business Officer, at elthomssen(at)armune(dot)com or by telephone, 269-491-6431.
About CLIA (http://www.cms.gov/clia)
The Clinical Laboratory Improvement Amendments of 1988 (CLIA) regulations include federal standards applicable to all U.S. facilities or sites that test human specimens for health assessment or to diagnose, prevent, or treat disease. CDC, in partnership with CMS and FDA, supports the CLIA program and clinical laboratory quality.
About Armune BioScience (http://www.armune.com)
Armune BioScience, Inc. is a medical diagnostics company that develops and commercializes unique proprietary technology exclusively licensed from the University of Michigan for diagnostic and prognostic tests for prostate, lung and breast cancers. The Company was founded by the Apjohn Group, LLC (http://www.apjohngroup.com), a business accelerator founded by experienced health care executives that brings together valuable resources of management talent and angel/seed financing, and a group of experienced life science professionals. Armune was incorporated as a Delaware Corporation with corporate headquarters in Kalamazoo, MI and a research and commercial laboratory in Ann Arbor, MI.